Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia.

Area of Science:

• Neurology
• Cognitive Science
• Neuropsychology

Background:

• Current criteria for Parkinson's disease mild cognitive impairment (PD-MCI) permit global cognitive tests.
• The predictive capability of these global tests for progression to Parkinson's disease dementia (PDD) remains unclear, especially when contrasted with detailed neuropsychological evaluations.

Purpose of the Study:

• To evaluate the predictive value of global cognitive tests versus comprehensive neuropsychological assessments for the conversion from PD-MCI to PDD.
• To compare the diagnostic accuracy and risk prediction capabilities of different assessment methods.

Main Methods:

• The MDS PD-MCI Study Group aggregated data from four datasets, including global cognitive tests and comprehensive neuropsychological assessments for 467 PD-MCI patients.
• Cox proportional hazards models were employed to analyze the risk of developing PDD.
• Global cognitive tests (MMSE, MoCA) were directly compared against neuropsychological test batteries (Level I & II) in predicting PDD risk.

Main Results:

• PD-MCI diagnosis using MMSE or MoCA significantly increased the hazard for PDD development (HR=2.57, P=0.001 for MMSE; HR=4.14, P<0.001 for MoCA).
• C-statistics indicated lower predictive power for MMSE (0.72) and MoCA (0.70) compared to neuropsychological tests (Level I=0.82, Level II=0.81).
• Level II neuropsychological assessment demonstrated the optimal balance of sensitivity, specificity, and diagnostic accuracy.

Conclusions:

• Both MMSE and MoCA are capable of predicting conversion to PDD.
• Comprehensive Level II neuropsychological assessment is recommended as the preferred method for evaluating PD-MCI due to its superior predictive accuracy.